UNSPSC 51284903: Cilastatin/imipenem

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM119. This VA Drug Class (AM119) classifies this compound as belonging to the group BETA-LACTAMS ANTIMICROBIALS, OTHER.

UNSPSC 51284903 Cilastatin/imipenem is a Commodity code for antibiotic pharmaceutical products; however, the recent state and local opportunities tagged under this code do not reflect procurement of cilastatin/imipenem itself. State and local governments buying under this code appear to use it for broader pharmaceutical warehousing and supply agreements, including antibiotic and emergency-response pharmaceuticals through piggyback contracts and direct procurement. The issuing bodies include state health departments and county governments, sourcing products through both cooperative purchasing consortiums (such as MMCAP Infuse) and competitive sealed bidding for specific therapeutic categories and emergency-response items.

Recent activity centers on Illinois and Florida. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026, valued at $2,999,999.11 over three years (including renewal options), for the supply of Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets through an Invitation for Bid process. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, with a response deadline of July 26, 2023) to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with an initial two-year contract term and one-year renewal option. The code shows limited recent activity and the opportunities recorded do not align with the cilastatin/imipenem commodity name, suggesting potential miscoding or that the code is used by these jurisdictions for warehouse and general pharmaceutical procurement rather than this specific drug formulation.